Artificial Intelligence Assisted Pharmacophore Design for Philadelphia Chromosome-Positive Leukemia with Gamma-Tocotrienol: A Toxicity Comparison Approach with Asciminib

BCR-ABL1 is a fusion protein as a result of a unique chromosomal translocation (producing the so-called Philadelphia chromosome) that serves as a clinical biomarker primarily for chronic myeloid leukemia (CML); the Philadelphia chromosome also occurs, albeit rather rarely, in other types of leukemia. This fusion protein has proven itself to be a promising therapeutic target. Exploiting the natural vitamin E molecule gamma-tocotrienol as a BCR-ABL1 inhibitor with deep learning artificial intelligence (AI) drug design, this study aims to overcome the present toxicity that embodies the currently provided medications for (Ph+) leukemia, especially asciminib. Gamma-tocotrienol was employed in an AI server for drug design to construct three effective de novo drug compounds for the BCR-ABL1 fusion protein. The AIGT’s (Artificial Intelligence Gamma-Tocotrienol) drug-likeliness analysis among the three led to its nomination as a target possibility. The toxicity assessment research comparing AIGT and asciminib demonstrates that AIGT, in addition to being more effective nonetheless, is also hepatoprotective. While almost all CML patients can achieve remission with tyrosine kinase inhibitors (such as asciminib), they are not cured in the strict sense. Hence it is important to develop new avenues to treat CML. We present in this study new formulations of AIGT. The docking of the AIGT with BCR-ABL1 exhibited a binding affinity of −7.486 kcal/mol, highlighting the AIGT’s feasibility as a pharmaceutical option. Since current medical care only exclusively cures a small number of patients of CML with utter toxicity as a pressing consequence, a new possibility to tackle adverse instances is therefore presented in this study by new formulations of natural compounds of vitamin E, gamma-tocotrienol, thoroughly designed by AI. Even though AI-designed AIGT is effective and adequately safe as computed, in vivo testing is mandatory for the verification of the in vitro results.

[1]  S. Sy,et al.  Exposure–Efficacy Analysis of Asciminib in Philadelphia Chromosome–Positive Chronic Myeloid Leukemia in Chronic Phase , 2022, Clinical pharmacology and therapeutics.

[2]  S. Sy,et al.  Population Pharmacokinetics of Asciminib in Tyrosine Kinase Inhibitor-Treated Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic and Acute Phases , 2022, Clinical Pharmacokinetics.

[3]  M. Mathai,et al.  Revisiting the therapeutic potential of tocotrienol , 2022, BioFactors.

[4]  R. Pappu,et al.  AlphaFold and implications for intrinsically disordered proteins. , 2021, Journal of molecular biology.

[5]  M. Bonifacio,et al.  Economic Model to Evaluate the Cost-Effectiveness of Second-Line Nilotinib Versus Dasatinib for the Treatment of Philadelphia Chromosome-Positive Chronic Myeloid Leukemia (CML-CP) in Italy , 2021, PharmacoEconomics - Open.

[6]  Junzhou Huang,et al.  WADDAICA: A webserver for aiding protein drug design by artificial intelligence and classical algorithm , 2021, Computational and structural biotechnology journal.

[7]  J. Cortes,et al.  Third-line therapy for chronic myeloid leukemia: current status and future directions , 2021, Journal of Hematology & Oncology.

[8]  J. Abdul-Ghafar,et al.  Philadelphia chromosome positive chronic myeloid leukemia with 5q deletion at diagnosis , 2021, Molecular Cytogenetics.

[9]  S. Cowan-Jacob,et al.  The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase. , 2020, Leukemia research.

[10]  P. le Coutre,et al.  Early molecular response in East African Philadelphia chromosome-positive chronic myeloid leukaemia patients treated with Imatinib and barriers to access treatment , 2020, Ecancermedicalscience.

[11]  Jerzy Leszczynski,et al.  Open access in silico tools to predict the ADMET profiling of drug candidates , 2020, Expert opinion on drug discovery.

[12]  A. Baruchel,et al.  Ponatinib in childhood Philadelphia chromosome-positive leukaemias: an international registry of childhood chronic myeloid leukaemia study. , 2020, European journal of cancer.

[13]  H. Kantarjian,et al.  Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring , 2020, American journal of hematology.

[14]  Tiziano Tuccinardi,et al.  Application of MM-PBSA Methods in Virtual Screening , 2020, Molecules.

[15]  Y. Mabkhot,et al.  Petra/Osiris/Molinspiration and Molecular Docking Analyses of 3-Hydroxy-Indolin-2-one Derivatives as Potential Antiviral Agents. , 2019, Current computer-aided drug design.

[16]  K. Yoo,et al.  Phase 2 Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia. , 2019, Blood.

[17]  Mario Medvedovic,et al.  Cheminformatics Tools for Analyzing and Designing Optimized Small-Molecule Collections and Libraries. , 2019, Cell chemical biology.

[18]  K. Chin,et al.  The Role of Tocotrienol in Protecting Against Metabolic Diseases , 2019, Molecules.

[19]  O. Ayyıldız,et al.  Frontline nilotinib treatment in Turkish patients with Philadelphia chromosome–positive chronic Myeloid Leukemia in chronic phase: updated results with 2 years of follow-up , 2018, Hematology.

[20]  Andreas Eckert,et al.  ProTox-II: a webserver for the prediction of toxicity of chemicals , 2018, Nucleic Acids Res..

[21]  Gianni De Fabritiis,et al.  DeepSite: protein‐binding site predictor using 3D‐convolutional neural networks , 2017, Bioinform..

[22]  Paul W Dickman,et al.  Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Eduardo Krempser,et al.  DockThor 2 . 0 : a Free Web Server for Protein-Ligand Virtual Screening , 2017 .